PERTH, AUSTRALIA: May 23, 2011 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today an extension of its collaboration with the Swiss Pharmaceutical company Roche relating to cell-penetrating peptides derived from Phylogica’s Phylomer drug discovery platform. Under the terms of the extended agreement, Phylogica has granted Roche an option to license a specific Phylomer peptide with demonstrated cell penetration activity for application to delivery across the blood-brain barrier.
“Following the success of the first stage of our research collaboration with Roche, we are delighted to have entered a new agreement that extends our relationship to blood-brain delivery of peptides. In partnership with Roche, we have identified unique cell-penetrating Phylomer peptides, some of which have the potential to cross the blood-brain barrier and could be used to develop novel treatments for neurological diseases. The discovery of biological drugs that can target neuronal cells has been a real challenge for the pharmaceutical industry in the past and so we are excited to be moving forward with Roche in this area.”
For further information please download PDF below:
